Acute Ischemic Stroke Clinical Trial
Official title:
Evaluation Of Human Urinary Kallidinogenase in Acute Stroke Patients: Magnetic Resonance Spectrum and CT Perfusion
Background: Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality
worldwide. Human urinary kallidinogenase (HUK), a glycoprotein extracted from male urine
currently used in China for enhancing cerebral perfusion5, plays a neuroprotective role
including promoting angiogenesis, enhancing cerebral perfusion and suppressing the
inflammatory response in animals and in patients with respect to regulating the
kallikrein-kinin system. In previous clinical research, neurological function scores and
cerebral perfusion scans were largely used to evaluate the efficiency of HUK. However, the
mechanisms of Further well-conducted, randomized controlled studies using HUK are currently
lacking.
Objective: To assess the Human urinary kallidinogenase effects on brain metabolite and
cerebral perfusion changes using magnetic resonance spectroscopy and CT perfusion in patients
with AIS.
Methods: The investigators plan to do a single-centre randomized, double-blind, controlled
trial in which ischemic stroke patients will be randomized to treatment with either HUK or
regular treatment within 72 hours of symptom onset. The study includes two MRS and two CTP
scannings (before and after 2 week treatment) for all randomized subjects.
The endpoints will include improvement of the NIH Stroke Scale (NIHSS) score from baseline,
modified Rankin scale (mRS) score and Barthel index at 14 days.
EvHUKMRS will test the following hypotheses:
1. HUK enhanced N-acetylaspartate (NAA) and cerebral blood flow (CBF) 14 days after
treatment compared with control group.
2. HUK group compared to control group when administered 72 hours after onset of AIS
improves recovery and functional outcome as assessed by improvement of NIHSS score , mRS
score and BI score on day 14 post-stroke.
A positive result will have a significant impact in the management of AIS and pave the way
for future studies aimed at finding the optimal dose and formulation of HUK for treating
acute ischemic stroke.
A)Specific Primary Objective:
1. To determine if HUK, administered within 72 hours of AIS onset is superior to regular
treatment in improving NAA values and CBF on day 14 post stroke.
B) Specific Secondary Objectives:
1. To determine if HUK, administered within 72 hours of AIS onset is superior to regular
treatment in reducing neurological deficit and improving functional outcome on day 14 post
stroke.
Recruitment of study subjects:
Acute ischemic stroke patients admitted to the Neurology department in XWh (Xuan hospital)
during the study period who are eligible to participate in this study based on criteria
stated above will be invited to participate in this study.
The time window for enrolment will be within 72 hours of symptom onset. All eligible patients
will be identified by the ward and on-call Neurology/Medical teams and referred to the study
research assistants or investigators; who will then screen the patient for participation in
this trial.
STUDY INTERVENTION The assigned treatment 0.15 PNA units of HUK injection or regular
treatment will be administered once daily for 14 consecutive days soon after informed consent
is taken and the patient is enrolled into the study.
Follow-up Assessment:
The neurologic deficits, global functional abilities and level of handicap will be scored
using the NIH Stroke Scale (NIHSS) and the modified Rankin scale (mRS) at baseline and on day
14(plus or minus 14 days).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 | |
Completed |
NCT01021319 -
Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)
|